16.68

0.69% -0.09

Acadia Pharmaceuticals Inc (ACAD)

Overview News Price History Option Chain Financials Why ACAD Down? Discussions Forecast

Acadia Pharmaceuticals Inc stock is traded at $16.68, with a volume of 271.63K. It is down -0.69% in the last 24 hours and down -15.76% over the past month. Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Previous Close:

$16.77

Open:

$16.67

24h Volume:

271.63K

Relative Volume:

0.12

Market Cap:

$2.79B

Revenue:

$890.53M

Net Income/Loss:

$30.57M

P/E Ratio:

92.67

EPS:

0.18

Net Cash Flow:

$80.53M

1W Performance:

-5.42%

1M Performance:

-15.76%

6M Performance:

+2.05%

1Y Performance:

-14.85%

1-Day Range:

$16.60

$16.91

1-Week Range:

$16.60

$17.86

52-Week Range:

$14.15

$20.68

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name

Acadia Pharmaceuticals Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

858-558-2871

Address

12830 EL CAMINO REAL, SAN DIEGO

Employee

654

Twitter

@acadiapharma

Next Earnings Date

2024-11-06

Latest SEC Filings

ACAD's Discussions on Twitter

Compare ACAD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACAD Acadia Pharmaceuticals Inc	16.68	2.79B	890.53M	30.57M	80.53M	0.18
VRTX Vertex Pharmaceuticals Inc	498.93	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	678.13	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	577.05	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	240.71	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.10	26.76B	3.32B	-860.46M	-1.04B	-8.32

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Deutsche Bank	Hold
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Mar-12-24	Downgrade	Mizuho	Buy → Neutral
Mar-12-24	Reiterated	Needham	Buy
Jan-30-24	Initiated	Robert W. Baird	Outperform
Jan-24-24	Upgrade	Needham	Hold → Buy
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold
Dec-13-23	Initiated	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-06-23	Upgrade	Mizuho	Neutral → Buy
Oct-17-23	Initiated	UBS	Buy
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy
Nov-04-22	Downgrade	Goldman	Neutral → Sell
Nov-01-22	Initiated	Loop Capital	Hold
Aug-08-22	Downgrade	Citigroup	Buy → Neutral
Aug-05-22	Downgrade	Citigroup	Buy → Neutral
Jun-21-22	Downgrade	Jefferies	Buy → Underperform
Jun-16-22	Upgrade	Jefferies	Hold → Buy
Mar-16-22	Upgrade	Canaccord Genuity	Hold → Buy
Feb-09-22	Upgrade	H.C. Wainwright	Neutral → Buy
Jan-05-22	Upgrade	Citigroup	Neutral → Buy
Dec-21-21	Downgrade	Guggenheim	Buy → Neutral
Nov-01-21	Upgrade	Guggenheim	Neutral → Buy
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Jun-10-21	Initiated	Berenberg	Hold
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-06-21	Downgrade	Canaccord Genuity	Buy → Hold
Apr-06-21	Downgrade	Goldman	Buy → Neutral
Apr-06-21	Downgrade	Jefferies	Buy → Hold
Apr-06-21	Downgrade	Mizuho	Buy → Neutral
Apr-05-21	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-10-21	Downgrade	BofA Securities	Buy → Neutral
Mar-09-21	Downgrade	Citigroup	Buy → Neutral
Mar-09-21	Downgrade	Guggenheim	Buy → Neutral
Mar-09-21	Reiterated	H.C. Wainwright	Buy
Mar-09-21	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-21	Downgrade	Stifel	Buy → Hold
Dec-16-20	Initiated	Mizuho	Buy
Nov-16-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Initiated	Morgan Stanley	Overweight
Jul-07-20	Upgrade	Stifel	Hold → Buy
Apr-16-20	Initiated	Jefferies	Buy
Mar-31-20	Upgrade	Goldman	Neutral → Buy
Mar-06-20	Initiated	Citigroup	Buy
Dec-16-19	Initiated	Guggenheim	Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-01-19	Initiated	RBC Capital Mkts	Outperform
Sep-13-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-10-19	Upgrade	Canaccord Genuity	Hold → Buy
Jul-23-19	Reiterated	Needham	Buy
Dec-10-18	Initiated	Canaccord Genuity	Hold
Sep-21-18	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-09-18	Reiterated	Stifel	Hold
Aug-07-18	Initiated	Stifel	Hold
Aug-06-18	Downgrade	Piper Jaffray	Overweight → Neutral
Oct-06-17	Resumed	Goldman	Neutral

View All

Acadia Pharmaceuticals Inc Stock (ACAD) Latest News

Mar 12, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com South Africa

Mar 12, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com India

Mar 12, 2025

Proficio Capital Partners LLC Invests $272,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World

Mar 12, 2025

Parkinson's Disease Therapeutics Market is expected to reach - openPR

Mar 12, 2025

Mar 11, 2025

ACADIA Pharmaceuticals Q4 Earnings: EPS Soars to $0.86, Beating Estimates, While Revenue Misses at $259.6 Million - GuruFocus.com

Mar 11, 2025

Mar 10, 2025

Calif. Pharma Exec Pleads Guilty To Insider Trading - Law360

Mar 10, 2025

SEC Sues Former Acadia Pharmaceuticals VP Over Insider Trading - Bloomberg Law

Mar 10, 2025

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigating ACAD for Possible Securities Law Violations - ACCESS Newswire

Mar 10, 2025

Mar 09, 2025

Former Vice President of San Diego-Based Acadia Pharmaceutical Company Admits to Insider Trading - Sierra Sun Times

Mar 09, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Equal Weight Rating from Morgan Stanley - Defense World

Mar 09, 2025

Mar 08, 2025

Ex-San Diego pharma VP pleads guilty to securities fraud for insider trading - ABC 10 News San Diego KGTV

Mar 08, 2025

Former San Diego Pharma VP pleads guilty to securities fraud for insider trading - NBC San Diego

Mar 08, 2025

Former Acadia Pharmaceuticals VP Pleads Guilty to Insider Trading in San Diego Federal Court - Hoodline

Mar 08, 2025

Former Executive Pleads Guilty to Insider Trading in FDA Drug Case - NewsBreak

Mar 08, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded at StockNews.com - Defense World

Mar 08, 2025

Ex-San Diego biotech company CEO admits to illegally selling $1.3M worth of shares - FOX 5 San Diego

Mar 08, 2025

Mar 07, 2025

Former Pharmaceutical Executive Pleads Guilty After $1.3M Gain from Insider Trading - Times of San Diego

Mar 07, 2025

Balanced Outlook for ACADIA Pharmaceuticals Amid Uncertain Long-term Growth Prospects - TipRanks

Mar 07, 2025

Insider Sell: Elizabeth Garofalo Sells 4,919 Shares of ACADIA Ph - GuruFocus.com

Mar 06, 2025

Acadia Pharmaceuticals director Elizabeth Garofalo sells $89,673 in stock By Investing.com - Investing.com South Africa

Mar 06, 2025

Acadia Pharmaceuticals director Elizabeth Garofalo sells $89,673 in stock - Investing.com India

Mar 06, 2025

Mar 05, 2025

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised) - MSN

Mar 05, 2025

How Biopharma Leaders Are Leveling Up Sales Strategies For 2025 - FiercePharma

Mar 05, 2025

Acadia reports DAYBUE safe for young Rett syndrome patients - Investing.com

Mar 05, 2025

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med - Yahoo Finance

Mar 05, 2025

Principal Financial Group Inc. Increases Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World

Mar 05, 2025

Can Acadia's Rett Syndrome Treatment Change Patient Lives? New Clinical Data Reveals Key Insights - StockTitan

Mar 05, 2025

Mar 04, 2025

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised) - MSN

Mar 04, 2025

New York State Common Retirement Fund Grows Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World

Mar 04, 2025

Mar 03, 2025

ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Simply Wall St

Mar 03, 2025

ACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 03, 2025

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study - The Bakersfield Californian

Mar 03, 2025

Can Acadia's New Essential Tremor Drug Candidate Survive Its Clinical Trial Pause? - StockTitan

Mar 03, 2025

Mar 02, 2025

Acadia Pharmaceuticals Ends FY2024 On Solid Footing (NASDAQ:ACAD) - Seeking Alpha

Mar 02, 2025

Truist Financial Corp Reduces Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World

Mar 02, 2025

ACADIA Pharmaceuticals’ (ACAD) “Buy” Rating Reiterated at Needham & Company LLC - Defense World

Mar 02, 2025

Mar 01, 2025

FY2025 EPS Estimates for ACAD Decreased by Cantor Fitzgerald - MarketBeat

Mar 01, 2025

Brokers Issue Forecasts for ACAD Q1 Earnings - MarketBeat

Mar 01, 2025

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Phocas Financial Corp. - MarketBeat

Mar 01, 2025

Los Angeles Capital Management LLC Grows Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Mar 01, 2025